Credential · Certification

LSVT LOUD

SLP47 citations · 3 lenses

50+ peer-reviewed studies. 5.05-point UPDRS-III motor improvement. Voice amplitude gains maintained at 2 years. ASHA-recognized evidence-based practice.

Scores · default weights
Clinical
66/100
Business
59/100
Academic Clinical
66/100

Each lens uses its own dimensions and default weights. Scores answer different questions across paths — they aren’t apples-to-apples. How scoring works →

Clinical breakdown
Clinical outcomes×35%
80/100

Robust voice amplitude and intelligibility gains in PD; neuroimaging shows cortical reorganization. 2-year maintenance documented.

Caseload applicability×15%
55/100

High value for SLPs treating Parkinson disease; limited applicability outside neuro-specific caseloads.

Billing & reimbursement×15%
52/100

Billed under speech therapy codes; Medicare and commercial cover; LSVT documentation supports medical necessity for voice treatment.

Certification investment×20%
48/100

4-day intensive course required; ~$500-600 fee; biennial recertification adds ongoing cost.

Employer demand×10%
82/100

Among the most employer-demanded SLP certifications for neuro outpatient; frequently required or preferred in job listings.

Patient experience×5%
76/100

Patients report meaningful communication improvement; family-reported quality of life gains significant in PD.

Business breakdown
Cash-pay viability×25%
55/100

PD families regularly pay cash for LSVT when insurance limits hit; one of the more cash-friendly SLP credentials.

Pricing leverage×20%
60/100

Branded, trademarked protocol commands premium pricing within SLP space.

Market differentiation×15%
70/100

Strong consumer-recognizable brand within the Parkinson's community; defensible niche.

Owner leverage×15%
65/100

Protocol is taught and staffable; LSVT-certified SLPs can deliver under a clinic brand.

Consumer demand×15%
55/100

PD support groups and neurologists actively refer to LSVT providers.

Credential investment×10%
50/100

Certification fee is meaningful (~$800+) and requires recertification.

Academic Clinical breakdown
Faculty recognition×25%
60/100

Recognized as legitimate evidence-based protocol in SLP academia.

Scholarship signal×20%
75/100

Strong publication pipeline from LSVT Global research team.

Teaching value×15%
70/100

Standard teaching exemplar in PD/neuro SLP coursework.

Evidence depth×20%
75/100

Multiple RCTs supporting efficacy in PD dysarthria.

Faculty demand×10%
50/100

Useful but not commonly required in SLP faculty postings.

Credential investment×10%
55/100

Moderate cost and time; reasonable academic ROI.

Evidence base · 47 sources
  1. 01
    Effects of Lee Silverman Voice Treatment‐BIG on Motor, Cognition, Mental Health, Occupational Performance, and Occupational Balance in Patients With Schizophrenia: A Single‐Subject Experimental Study
    W.-H. Jang; S.-M. Seo; S.-H. Kim; C. Hilton · Occupational Therapy International2025
    Otherdoi:10.1155/oti/3566653
  2. 02
    Efficacy of in-person and telepractice-based extended Lee Silverman Voice Treatment LOUD(®) on dysarthria and dysphagia in adults with cerebral palsy
    K. M. Kim; S. A. Park; S. H. Hwang; A. Park; H. H. Kim; J. Hwang; S. R. Cho · Digit Health2025
    Otherdoi:10.1177/20552076251315296
  3. 03
    The PD COMM Process Evaluation: Describing Interventions and Implementation in a UK Pragmatic Randomised Controlled Trial of Speech and Language Therapy for People With Parkinson's-Related Dysarthria
    A. Nicoll; M. C. Brady; P. Masterson-Algar; C. Burton; G. Beaton; S. Dickson; M. Caulfield; C. H. Smith; C. E. Clarke; N. Ives; S. Jowett; C. Rick; R. Woolley; C. M. Sackley · Int J Lang Commun Disord2025
    RCTdoi:10.1111/1460-6984.70084
  4. 04
    Effects of LSVT LOUD and EMST in individuals with Parkinson's disease: A two arm non-randomized clinical trial
    S. Saleem; A. Miles; J. Allen · Int J Speech Lang Pathol2025
    RCTdoi:10.1080/17549507.2025.2455635
  5. 05
    Efficacy of LSVT LOUD(®) on Phonatory Control and Voice Quality in Patients with Primary Progressive Apraxia of Speech: Case Studies
    Y. N. C. Choi; V. Martel-Sauvageau; M. Breton; M. Lavoie; R. Laforce, Jr.; L. Bouvier · Brain Sci2024
    Case seriesdoi:10.3390/brainsci14050417
  6. 06
    The impact of PD Check-In on self-management skills for maintenance of speech after intensive treatment
    A. Finnimore; D. Theodoros; A. F. Rumbach · Int J Lang Commun Disord2024
    Otherdoi:10.1111/1460-6984.13024
  7. 07
    Effectiveness of Lee Silverman Voice Treatment (LSVT-LOUD) in Parkinsonian-Type Multiple System Atrophy (MSA-P): A Case Report
    K. Hayashi; R. Izumi; N. Saito; A. Suzuki; Y. Nakaya; M. Sato; Y. Kobayashi · Cureus2024
    Case seriesdoi:10.7759/cureus.73106
  8. 08
    ¿Notas La Diferencia? [Do You Hear the Difference?]: Perceptual Consequences of Intensive Voice Treatment in Spanish Speakers With Parkinson's Disease
    G. Moya-Galé; J. D. Hernández; A. Goudarzi; S. J. Walsh · Journal of Speech, Language & Hearing Research2024
    Otherdoi:10.1044/2023_JSLHR-23-00379
  9. 09
    The Acoustic Voice Quality Index (AVQI) in People with Parkinson's Disease Before and After Intensive Voice and Articulation Therapies: Secondary Outcome of a Randomized Controlled Trial
    G. Moya-Galé; J. Spielman; L. A. Ramig; L. Campanelli; Y. Maryn · Journal of Voice2024
    RCTdoi:10.1016/j.jvoice.2022.03.014
  10. 10
    LSVT as a fundamental therapeutic technique for improving voice in parkinsonism: Evidence from three cases
    N. Narayanan; Z. N. Rahman · Annals of Movement Disorders2024
    Otherdoi:10.4103/aomd.aomd_36_23
  11. 11
    The Effectiveness of Lee Silverman Voice Treatment (LSVT LOUD) on Children's Speech and Voice: A Scoping Review
    A. Papadopoulos; L. Voniati; N. Ziavra; D. Tafiadis · Brain Sci2024
    Systematic reviewdoi:10.3390/brainsci14090937
  12. 12
    Behavioral Management of Respiratory/Phonatory Dysfunction for Dysarthria Associated With Neurodegenerative Disease: A Systematic Review
    S. E. Perry; M. Troche; J. E. Huber; J. Curtis; B. Kiefer; J. Sevitz; Q. Dennard; J. Borders; J. R. Browy; A. Dakin; V. Gonzalez; J. Chapman; T. Wu; L. Katz; D. Britton · Am J Speech Lang Pathol2024
    Systematic reviewdoi:10.1044/2023_ajslp-23-00274
  13. 13
    Narrative analysis in individuals with Parkinson's disease following intensive voice treatment: secondary outcome variables from a randomized controlled trial
    A. E. Ramage; K. J. Greenslade; K. Cote; J. N. Lee; C. M. Fox; A. Halpern; L. O. Ramig · Front Hum Neurosci2024
    RCTdoi:10.3389/fnhum.2024.1394948
  14. 14
    The effect of two speech and language approaches on speech problems in people with Parkinson's disease: the PD COMM RCT
    C. M. Sackley; C. Rick; M. C. Brady; C. Burton; S. Jowett; S. Patel; R. Woolley; P. Masterson-Algar; A. Nicoll; C. H. Smith; Z. Abdali; N. Ives; G. Beaton; S. Dickson; R. Ottridge; H. Nankervis; C. E. Clarke · Health Technol Assess2024
    RCTdoi:10.3310/adwp8001
  15. 15
    Lee Silverman voice treatment versus NHS speech and language therapy versus control for dysarthria in people with Parkinson's disease (PD COMM): pragmatic, UK based, multicentre, three arm, parallel group, unblinded, randomised controlled trial
    C. M. Sackley; C. Rick; M. C. Brady; R. Woolley; C. Burton; S. Patel; P. Masterson-Algar; A. Nicoll; C. H. Smith; S. Jowett; N. Ives; G. Beaton; S. Dickson; R. Ottridge; L. Sharp; H. Nankervis; C. E. Clarke · Bmj2024
    RCTdoi:10.1136/bmj-2023-078341
  16. 16
    Intensive Voice Treatment following Botulinum Neurotoxin Injection for a Speaker with Abductor Laryngeal Dystonia: An Exploratory Case Study
    M. Schnell; D. Slavin · Seminars in Speech & Language2024
    Case seriesdoi:10.1055/s-0044-1779509
  17. 17
    Case Report: Benefits of LSVT LOUD in a multilingual patient with hypokinetic-hyperkinetic dysarthria and suspected progressive supranuclear palsy
    A. Sebestyen; A. Hilger; H. Kleiber · Frontiers in Rehabilitation Sciences2024
    Case seriesdoi:10.3389/fresc.2024.1421730
  18. 18
    Hypokinetic Dysarthria in Parkinson's Disease: A Narrative Review
    M. S. Atalar; O. Oguz; G. Genc · Sisli Etfal Hastan Tip Bul2023
    Narrative reviewdoi:10.14744/semb.2023.29560
  19. 19
    Factors Associated With Treatment-Related Changes in Voice Volume in People With Multiple Sclerosis
    V. Crispiatico; C. Baldanzi; M. Bertuletti; S. Grassi; F. Tedeschi; E. Groppo; M. Rovaris; D. Cattaneo; C. Vitali · International Journal of MS Care2023
    Otherdoi:10.7224/1537-2073.2021-056
  20. 20
    Clinical outcomes of PD Check-In, a model for supported self-managed maintenance of speech in Parkinson's disease: A Phase 1 study
    A. Finnimore; D. Theodoros; A. F. Rumbach · Int J Lang Commun Disord2023
    Otherdoi:10.1111/1460-6984.12772
  21. 21
    Report on the Impact of LSVT LOUD in Improving Communication of a Preschool Child and a Young Adult With Cerebral Palsy
    A. J. Fortin; A. Hamel; F. Asselin-Giguère; S. Poulin; D. H. McFarland · Canadian Journal of Speech-Language Pathology & Audiology2023
    OtherPMID 173208927
  22. 22
    Conversational Vocal Intensity in Parkinson's Disease: Treatment and Environmental Comparisons
    R. Konnai; M. Van Harn; A. Silbergleit · Journal of Voice2023
    Otherdoi:10.1016/j.jvoice.2021.04.019
  23. 23
    Crowdsourced Perceptual Ratings of Voice Quality in People With Parkinson’s Disease Before and After Intensive Voice and Articulation Therapies: Secondary Outcome of a Randomized Controlled Trial
    T. McAllister; C. Nightingale; G. Moya-Galé; A. Kawamura; L. O. Ramig · Journal of Speech, Language & Hearing Research2023
    RCTdoi:10.1044/2023_JSLHR-22-00694
  24. 24
    Telerehabilitation for Lee Silverman Voice Treatment (Tele-LSVT)-Loud on voice intensity and voice use in daily living in people with multiple sclerosis: A protocol for a feasibility and pilot randomized controlled study
    C. Vitali; G. Fusari; C. Baldanzi; D. M. Cacciatore; V. Crispiatico; A. Carullo; M. Rovaris; D. Cattaneo; F. Baglio; S. Isernia · Digit Health2023
    RCTdoi:10.1177/20552076231218150
  25. 25
    Effects of Intensive Voice Treatment (The Lee Silverman Voice Treatment [LSVT LOUD]) in Subjects With Multiple Sclerosis: A Pilot Study
    C. Baldanzi; V. Crispiatico; S. Foresti; E. Groppo; M. Rovaris; D. Cattaneo; C. Vitali · Journal of Voice2022
    Pilot/feasibilitydoi:10.1016/j.jvoice.2020.07.025
  26. 26
    Intensive Voice Treatment (Lee Silverman Voice Treatment [LSVT LOUD]) for Children With Down Syndrome: Phase I Outcomes
    C. A. Boliek; A. Halpern; K. Hernandez; C. M. Fox; L. Ramig · Journal of Speech, Language & Hearing Research2022
    Otherdoi:10.1044/2021_JSLHR-21-00228
  27. 27
    Effects of voice rehabilitation in people with MS: A double-blinded long-term randomized controlled trial
    V. Crispiatico; C. Baldanzi; A. Napoletano; L. Tomasoni; F. Tedeschi; E. Groppo; M. Rovaris; C. Vitali; D. Cattaneo · Mult Scler2022
    RCTdoi:10.1177/13524585211051059
  28. 28
    Intensive voice treatment (the Lee Silverman Voice Treatment [LSVT<sup>®</sup>LOUD]) for individuals with Wilson's disease and adult cerebral palsy: two case reports
    E. Ertan; H. I. Gürvit; H. H. Hanağası; B. Bilgiç; M. A. Tunçer; C. Yılmaz · Logopedics Phoniatrics Vocology2022
    Otherdoi:10.1080/14015439.2021.1951348
  29. 29
    The Impact of PD Check-In, a Model for Supported Self-Managed Maintenance of Speech on the Quality of Life of People with Parkinson's Disease: A Phase 1 Study
    A. Finnimore; D. Theodoros; A. Rumbach · Brain Sci2022
    Otherdoi:10.3390/brainsci12040433
  30. 30
    PD Check-In: The development and trial of a supported self-management program for people with Parkinson's disease following intensive speech intervention
    A. Finnimore; D. Theodoros; A. F. Rumbach · Int J Lang Commun Disord2022
    Otherdoi:10.1111/1460-6984.12682
  31. 31
    Multidimensional voice assessment after Lee Silverman Voice Therapy (LSVT(®)) in Parkinson's disease
    M. R. Marchese; I. Proietti; Y. Longobardi; G. Mari; C. Ausili Cefaro; L. D'Alatri · Acta Otorhinolaryngol Ital2022
    Otherdoi:10.14639/0392-100x-n1962
  32. 32
    LSVT LOUD ® Applied to an Adult With Cerebral Palsy: Acoustic Findings
    G. Moya-Galé; J. Galgano; C. Ferrone; Y. M. Chang; L. A. Ramig · Communication Disorders Quarterly2022
    Otherdoi:10.1177/1525740121993802
  33. 33
    Immediate and long-term effects of speech treatment targets and intensive dosage on Parkinson's disease dysphonia and the speech motor network: Randomized controlled trial
    S. Narayana; C. Franklin; E. Peterson; E. J. Hunter; D. A. Robin; A. Halpern; J. Spielman; P. T. Fox; L. O. Ramig · Hum Brain Mapp2022
    RCTdoi:10.1002/hbm.25790
  34. 34
    Swallowing Outcomes Following Voice Therapy in Multiple System Atrophy with Dysphagia: Comparison of Treatment Efficacy with Parkinson's Disease
    A. Park; S. J. Jang; N. E. Kim; T. H. Kim; Y. H. Sohn; H. Kim; S. R. Cho · Dysphagia2022
    Otherdoi:10.1007/s00455-021-10265-9
  35. 35
    Respiratory Responses to Two Voice Interventions for Parkinson's Disease
    K. Richardson; J. E. Huber; B. Kiefer; C. Kane; S. Snyder · Journal of Speech, Language &amp; Hearing Research2022
    Otherdoi:10.1044/2022_JSLHR-22-00262
  36. 36
    Perception of Physical Demand, Mental Demand, and Performance: A Comparison of Two Voice Interventions for Parkinson's Disease
    K. Richardson; J. E. Huber; B. Kiefer; S. Snyder · American Journal of Speech-Language Pathology2022
    Otherdoi:10.1044/2022_AJSLP-22-00026
  37. 37
    Cost analysis of home telerehabilitation for speech treatment in people with Parkinson's disease
    M. Saiyed; A. J. Hill; T. G. Russell; D. G. Theodoros; P. Scuffham · J Telemed Telecare2022
    Otherdoi:10.1177/1357633x20948302
  38. 38
    The impact of Lee Silverman Voice Treatment (LSVT LOUD®) on voice, communication, and participation: Findings from a prospective, longitudinal study
    L. A. Bryans; A. D. Palmer; S. Anderson; J. Schindler; D. J. Graville · Journal of Communication Disorders2021
    Cohort studydoi:10.1016/j.jcomdis.2020.106031
  39. 39
    Neurobehavioral Effects of LSVT(®) LOUD on Auditory-Vocal Integration in Parkinson's Disease: A Preliminary Study
    Y. Li; M. Tan; H. Fan; E. Q. Wang; L. Chen; J. Li; X. Chen; H. Liu · Front Neurosci2021
    Otherdoi:10.3389/fnins.2021.624801
  40. 40
    Evaluation of an intensive voice treatment to reduce anterior drooling in children with cerebral palsy: Protocol for a concurrent multiple-baseline, single case experimental design study
    M. McInerney; C. Imms; P. N. Carding; D. S. Reddihough · Contemp Clin Trials Commun2021
    Study protocoldoi:10.1016/j.conctc.2021.100872
  41. 41
    Effects of Lee Silverman Voice Treatment (LSVT LOUD) on Swallowing in Patients with Progressive Supranuclear Palsy: A Pilot Study
    S. Nozaki; M. Fujiu-Kurachi; T. Tanimura; K. Ishizuka; E. Miyata; S. Sugishita; T. Imai; M. Nishiguchi; M. Furuta; S. Yorifuji · Prog Rehabil Med2021
    Pilot/feasibilitydoi:10.2490/prm.20210012
  42. 42
    Lee Silverman Voice Treatment to Improve Speech in Parkinson's Disease: A Systemic Review and Meta-Analysis
    T. Pu; M. Huang; X. Kong; M. Wang; X. Chen; X. Feng; C. Wei; X. Weng; F. Xu · Parkinson's Disease (20420080)2021
    Meta-analysisdoi:10.1155/2021/3366870
  43. 43
    Single Word Intelligibility of Individuals with Parkinson's Disease in Noise: Pre-Specified Secondary Outcome Variables from a Randomized Control Trial (RCT) Comparing Two Intensive Speech Treatments (LSVT LOUD vs. LSVT ARTIC)
    G. Schulz; A. Halpern; J. Spielman; L. Ramig; I. Panzer; A. Sharpley; K. Freeman · Brain Sci2021
    RCTdoi:10.3390/brainsci11070857
  44. 44
    Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial
    S. Scobie; S. Jowett; T. Lambe; S. Patel; R. Woolley; N. Ives; C. Rick; C. Smith; M. C. Brady; C. Clarke; C. Sackley · Pilot Feasibility Stud2021
    RCTdoi:10.1186/s40814-021-00888-y
  45. 45
    Feasibility and Acceptability of Lee Silverman Voice Treatment in Progressive Ataxias
    A. Lowit; A. Egan; M. Hadjivassiliou · Cerebellum2020
    Pilot/feasibilitydoi:10.1007/s12311-020-01153-3
  46. 46
    A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial
    C. M. Sackley; C. Rick; P. Au; M. C. Brady; G. Beaton; C. Burton; M. Caulfield; S. Dickson; F. Dowling; M. Hughes; N. Ives; S. Jowett; P. Masterson-Algar; A. Nicoll; S. Patel; C. H. Smith; R. Woolley; C. E. Clarke; P. C. C. Group · Trials2020
    RCTdoi:10.1186/s13063-020-04354-7
  47. 47
    Lee Silverman Voice Treatment for dysarthria in patients with Parkinson's disease: a systematic review and meta-analysis
    F. Yuan; X. Guo; X. Wei; F. Xie; J. Zheng; Y. Huang; Z. Huang; Z. Chang; H. Li; Y. Guo; J. Chen; J. Guo; B. Tang; B. Deng; Q. Wang · Eur J Neurol2020
    Meta-analysisdoi:10.1111/ene.14399
Try this credential against your own weights
Open in the interactive matrix — switch lenses, dial dimensions up or down, share a custom view by URL.
Open in matrix
Read the methodologyBack to CE Shield